ReqMed advocates a brand-new concept model in drug development that links to licensing activities. ReqMed conducts the initial clinical development for partner companies’ promising drug projects in Japan, thereby shortening the domestic development period and maximizing the drug’s value. In collaboration with research institutes and CROs in Japan and overseas, ReqMed will implement a quick POC program to obtain POC* quickly, contributing to a significant reduction of development risks for partner companies.
*POC: Abbreviation for Proof of Concept. POC: Proof of concept. Proof of a drug’s efficacy in patients.